Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
Nature Medicine
|
April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
The Lancet. Gastroenterology & Hepatology
|
July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Maeve A Lowery, Howard A Burris, Filip Janku, et al.
Oncogene
|
July 11, 2026
Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset
Jingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Harshabad Singh, Joanne Xiu, Kevin S Kapner, et al.
Journal of Hepatology
|
February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
Jennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients
Valerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
The Lancet. Oncology
|
May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
Nature Medicine
|
April 14, 2026
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial
Devalingam Mahalingam, Rachna T Shroff, Benedito A Carneiro, et al.
The Lancet. Gastroenterology & Hepatology
|
July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Maeve A Lowery, Howard A Burris, Filip Janku, et al.
Oncogene
|
July 11, 2026
Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset
Jingyuan Wang, Joanne Xiu, Francesca Battaglin, et al.
Nature Communications
|
September 30, 2025
Engineered exosomes with Kras<sup>G12D</sup> specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Valerie S Kalluri, Brandon G Smaglo, Krishnan K Mahadevan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Harshabad Singh, Joanne Xiu, Kevin S Kapner, et al.
Journal of Hepatology
|
February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
Jennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 17, 2025
KRAS <sup>G12D</sup> -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients
Valerie S LeBleu, Brandon G Smaglo, Krishnan K Mahadevan, et al.
The Lancet. Oncology
|
May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 16, 2020
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D Gordan, Erin B Kennedy, Ghassan K Abou-Alfa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Page
of 8